Andrew Johnstone
Family Medicine · Indianapolis, INNPI 1508831140
Payments from drug & device makers
Across 292 payments — averaging $12.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$551
- Boehringer Ingelheim$189
- Lilly USA, LLC$173
- Amgen$172
- Kowa Pharmaceuticals America, Inc.$156
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,76099%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,792 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $44,371 |
| JardianceEmpagliflozin | 22 | $23,921 |
| RexultiBrexpiprazole | 14 | $20,715 |
| VraylarCariprazine Hcl | 14 | $20,363 |
| EliquisApixaban | 22 | $18,137 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,432 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 214 | $6,664 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,493 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 96 | $4,039 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $3,894 |
| Ondansetron Hcl | 11 | $3,882 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,797 |
| Oxycodone Hcl | 141 | $3,732 |
| Liothyronine Sodium | 76 | $3,340 |
| Testosterone | 12 | $3,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $551 | $44,37134 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $189 | $30,41436 claims |
| AbbVieVraylar, Synthroid | $1,074 | $21,92640 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $55 | $20,71514 claims |
| PfizerEliquis | $35 | $18,13722 claims |
| AstraZenecaSymbicort | $148 | $3,79714 claims |
| Lilly USA, LLCOlanzapine | $173 | $47415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Blair BrengleIndianapolis$10.6M
- Steven SmithIndianapolis$2.5M
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Gaylen KeltonIndianapolis$42K
- Daniela LoboIndianapolis$38K
- Haihong MaoIndianapolis$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.